Another study showed IL-2 improved anti-CTLA-4 efficacy in mouse models of fibrosarcoma and colon carcinoma.78 In patients, however, the objective response rate of IL-2 and anti-CTLA-4 combination was not superior to single treatment, although some patients showed durable cancer regressions on combined treatment.79 The gene discussed is IL2; the disease is colon carcinoma.